scholarly journals CT‐based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration‐naïve oligometastatic prostate cancer

The Prostate ◽  
2020 ◽  
Vol 81 (2) ◽  
pp. 127-134
Author(s):  
Sara Sheikhbahaei ◽  
Diane K. Reyes ◽  
Steven P. Rowe ◽  
Kenneth J. Pienta
Keyword(s):  
Prostate Cancer ◽  
Body Composition ◽  
Chemohormonal Therapy ◽  
Oligometastatic Prostate Cancer

scholarly journals Radiotherapy of oligometastatic prostate cancer: a systematic review

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Paul Rogowski ◽  
Mack Roach ◽  
Nina-Sophie Schmidt-Hegemann ◽  
Christian Trapp ◽  
Rieke von Bestenbostel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Predictive Factors ◽  
Therapeutic Potential ◽  
Case Series ◽  
Current Evidence ◽  
Oligometastatic Disease ◽  
Psma Pet ◽  
Oligometastatic Prostate Cancer ◽  
Prognostic And Predictive Factors

Abstract Background Due to improved imaging sensitivity, the term “oligometastatic” prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy (MDT). There are two types of radiation based MDT applied when treating oligometastatic disease: (1) stereotactic body radiation therapy (SBRT) generally used for bone metastases; or (2) SBRT for isolated nodal oligometastases combined with prophylactic elective nodal radiotherapy. This review aims to summarize current evidence data, which may shed light on the optimal management of this heterogeneous group of patients. Methods A systematic review of the Medline database through PubMed was performed according to PRISMA guidelines. All relevant studies published up to November 2020 were identified and screened. Fifty-six titles were included. Besides outcome parameters, different prognostic and predictive factors were assessed, including site of metastases, time between primary treatment and MDT, use of systemic therapies, hormone sensitivity, as well as pattern of recurrence. Findings Evidence consists largely of retrospective case series and no consistent precise definition of oligometastasis exists, however, most investigators seem to acknowledge the need to distinguish between patients presenting with what is frequently called “synchronous” versus “metachronous” oligometastatic disease. Available data on radiotherapy as MDT demonstrate high local control rates and a small but relevant proportion of patients without progressive disease after 2 years. This holds true for both hormone sensitive and castration resistant prostate cancer diseases. The use of 68Ga-PSMA PET/CT for staging increased dramatically. Radiation doses and field sizes varied considerably among the studies. The search for relevant prognostic and predictive factors is ongoing. Conclusions To our best knowledge this review on oligometastatic prostate cancer included the largest number of original articles. It demonstrates the therapeutic potential and challenges of MDT for oligometastatic prostate cancer. Prospective studies are under way and will provide further high-level evidence.

scholarly journals Body composition and metastatic prostate cancer survivorship

2021 ◽  
Vol 27 ◽  
pp. 100322
Author(s):  
Adriana M Coletta ◽  
Nicolas Sayegh ◽  
Neeraj Agarwal
Keyword(s):  
Prostate Cancer ◽  
Body Composition ◽  
Cancer Survivorship ◽  
Metastatic Prostate Cancer

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer: Where is the Evidence?

2021 ◽  
Vol 33 (1) ◽  
pp. e94
Author(s):  
F.R. Macbeth ◽  
R.P. Abratt
Keyword(s):  
Prostate Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Oligometastatic Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document